Company intelligence
Amarin Corporation
Advancing cardiovascular care through science, innovation, and a commitment to better patient outcomes worldwide
About Amarin Corporation
Amarin is a global pharmaceutical company committed to reducing the cardiovascular disease (CVD) burden for patients and communities and to advancing the science of cardiovascular care around the world. We own and support a global branded product approved by multiple regulatory authorities based on a track record of proven efficacy and safety and backed by robust clinical trial evidence. Our commercialization model includes a direct sales approach in the U.S. and an indirect distribution strategy internationally through a syndicate of reputable and well-established partners with significant geographic expertise, covering over 90 markets worldwide. Our success is driven by a dedicated, talented, and highly skilled team of experts passionate about the fight against the world’s leading cause of death, CVD. For more information, visit www.amarincorp.com. See our Community Guidelines: bit.ly/2L7xEW6
Verified activity
Signals from Amarin Corporation
3 published signals
Presence & Recognition
Amarin Corporation is supporting the upcoming live Academy of Physician Associates In Cardiology webinar featuring Deepak L. Bhatt, MD, MPH, MBA and Viet Le, PA-C DMSc FACC FAHA FASPC HF-Cert discussing REDUCE-IT analyses presented at ESC Congress 2026 on September 9.
Reported by Amarin Corporation
Presence & Recognition
Amarin Corporation hosted its second annual Global Partners Meeting during the European Society of Cardiology Congress 2026 to exchange scientific and commercial insights, share market experiences, and strengthen collaboration.
Reported by Amarin Corporation
Presence & Recognition
Amarin Corporation participated in ESC Congress 2026 and highlighted scientific research events.
Reported by Amarin Corporation